Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Jae H. Park, Elias Jabbour, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Justin Shang, Claire Roddie

Blood (2024) 144 (Supplement 1): 3458.

https://doi.org/10.1182/blood-2024-201514

Published: 2024

Journal Articles

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Blood (2024) 144 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2024-207125

Published: 2024

Journal Articles

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood (2024) 144 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2024-206169

Published: 2024

Journal Articles

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Blood (2024) 144 (Supplement 1): 380.

https://doi.org/10.1182/blood-2024-204010

Published: 2024

Journal Articles

Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach

Ji Eun Lim, Srideshikan Sargur Madabushi, Mengistu Lemecha Shukare, Hemendra Ghimire, Jenny Paredes, Sally Mokhtari, James F. Sanchez, Karamjeet S Sandhu, Amandeep Salhotra, Ryotaro Nakamura, Jeffrey Wong, Anthony S. Stein, Dorothy Schaue, Marcel R.M. van den Brink, MHD Monzr M. Al Malki, Guy Storme, Susanta Hui

Blood (2024) 144 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2024-210774

Published: 2024

Journal Articles

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

Elias Jabbour, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Pierre Lao-Sirieix, Wolfram Brugger, Martin A Pule, Yiyun Zhang, Claire Roddie

Blood (2024) 144 (Supplement 1): 963.

https://doi.org/10.1182/blood-2024-194508

Published: 2024

Journal Articles

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Blood (2024) 144 (Supplement 1): 729.

https://doi.org/10.1182/blood-2024-208674

Published: 2024

Journal Articles

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Claire Roddie, Jae H. Park, Paul Shaughnessy, Aaron C. Logan, Karamjeet S Sandhu, Mehrdad Abedi, Bijal D Shah, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin A Pule, Justin Shang, Elias Jabbour

Blood (2024) 144 (Supplement 1): 4845.

https://doi.org/10.1182/blood-2024-208028

Published: 2024

Journal Articles

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Bijal D Shah, Jeremy Pantin, Karamjeet S Sandhu, Elias Jabbour, Jae H. Park, Paul Shaughnessy, Mehrdad Abedi, Michael R Bishop, Daniel J. DeAngelo, Wolfram Brugger, Martin Brown, Dilip Patel, Claire Roddie, Aaron C. Logan

Blood (2024) 144 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2024-205694

Published: 2024

Journal Articles

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Tamer Othman, John H. Baird, Yan Wang, Stacy Pak, Ibrahim Aldoss, Ji-Lian Cai, Alexey Danilov, Tycel J. Phillips, Vaibhav Agrawal, Karamjeet S Sandhu, Matthew Mei, Paul B. Koller, Joycelynne Michelle Palmer, Stephen J. Forman, Lihua E. Budde, Ahmed Aribi

Blood (2024) 144 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2024-207085

Published: 2024

Journal Articles

Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Anthony S. Stein, Jianying Zhang, Lucy Y. Ghoda, Marjorie Robbins, Cindy Croslin, Banafsheh Sinaki, Ahmed Aribi, Amanda Blackmon, Hoda Pourhassan, Brian J. Ball, Ibrahim Aldoss, Ryotaro Nakamura, MHD Monzr M. Al Malki, Karamjeet S Sandhu, Guido Marcucci

Blood (2024) 144 (Supplement 1): 4264.

https://doi.org/10.1182/blood-2024-205980

Published: 2024

Journal Articles

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Blood (2024) 144 (Supplement 1): 4935.

https://doi.org/10.1182/blood-2024-210956

Published: 2024

Journal Articles

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Karamjeet S. Sandhu, John Altin, Tao Wang, Jakob Devos, Medhat Askar, Zachariah DeFilipp, Ketevan Gendzekhadze, Carrie L. Kitko, Stephanie J. Lee, Margaret L. MacMillan, Stephen R. Spellman, Ryotaro Nakamura

Blood (2023) 142 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2023-186724

Published: 2023

Journal Articles

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2023-187460

Published: 2023

Journal Articles

Single Center Retrospective Study of Midostaurin Plus Intensive Chemotherapy for Older Patients with Newly Diagnosed FLT-3 Mutated Acute Myelogenous Leukemia

Blood (2023) 142 (Supplement 1): 5937.

https://doi.org/10.1182/blood-2023-173978

Published: 2023

Journal Articles

Concurrent Versus Sequential or No Triazole Anti-Fungal Therapy in Patients Undergoing 7+3 Plus Midostaurin Induction for FLT-3 Acute Myelogenous Leukemia

Dat Ngo, Jose Tinajero, Jianying Zhang, Anthony Stein, Guido Marcucci, Amandeep Salhotra, Vinod Pullarkat, Karamjeet S. Sandhu, Brian J. Ball, Paul B. Koller

Blood (2023) 142 (Supplement 1): 5932.

https://doi.org/10.1182/blood-2023-173973

Published: 2023

Journal Articles

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

Blood (2023) 142 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2023-187687

Published: 2023

Journal Articles

A Phase II Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Zachariah Defilipp, Haesook T. Kim, Guang-Shing Cheng, Saurabh Chhabra, Mehdi Hamadani, Karamjeet S. Sandhu, Betty K. Hamilton, Lia Perez, Catherine J. Lee, Timothy L Brennan, Cassandra Garrelts, Bergin M Brown, Kathleen Gallagher, Areej El-Jawahri, Yi-Bin Chen

Blood (2023) 142 (Supplement 1): 775.

https://doi.org/10.1182/blood-2023-179365

Published: 2023

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Blood (2023) 142 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2023-185034

Published: 2023

NARROW

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the Open-Label, Multi-Center, Global, Single-Arm, Phase Ib/II FELIX Study: The Impact of Bridging Therapies on CAR T-Cell Expansion and Persistence

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach

Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes

TP53 Mutations Increased the Risk of CD19 Negative Relapse Following Blinatumomab in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Risk Factors Associated with Sub-Optimal Outcomes Following Obecabtagene autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): What We Have Learned from the FELIX Trial

Healthcare Resource Utilization and Costs Associated with Managing CRS and ICANS in Patients with Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia Receiving Obecabtagene autoleucel (obe-cel)

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Phase 1 Trial of Navitoclax/Venetoclax/Decitabine Combination in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Outcomes of Hypomethylating Agents/Venetoclax (HMA/VEN) Treatment for Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Toxicities Associated with Tyrosine Kinase Inhibitor Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Single Center Retrospective Study of Midostaurin Plus Intensive Chemotherapy for Older Patients with Newly Diagnosed FLT-3 Mutated Acute Myelogenous Leukemia

Concurrent Versus Sequential or No Triazole Anti-Fungal Therapy in Patients Undergoing 7+3 Plus Midostaurin Induction for FLT-3 Acute Myelogenous Leukemia

Outcomes of Patients Undergoing Fludarabine and Melphalan-Based Conditioning with Post-Transplant Cyclophosphamide for Peripheral Blood Stem Cell Allogeneic Hematopoietic Cell Transplant: Donor Type Effect

A Phase II Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only